BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, March 16, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 27, 2015
View Archived Issues
New RNAi drug using extrahepatic delivery platform shows promise for metastatic ccRCC
Read More
Targeting retinal VEGR receptors, a promising strategy for retinal angiogenesis disorders
Read More
Malaria protein targets toxins to cancer cells
Read More
Grifols opens Bioscience Division global operations facility in Ireland
Read More
ABT-126 shows antidyskinetic effects in animal models
Read More
CDRD and viDA Therapeutics partner to discover treatments for DLE
Read More
Roche reports third quarter 2015 progress
Read More
Vasculotide, a potential treatment of Alzheimer's disease
Read More
TRPV1 and TRPA1 activation reduces muscular cramps
Read More
Acalabrutinib receives U.S. orphan designation for Waldenstrom macroglobulinemia
Read More
Auris Medical and King's College London to collaborate on small-molecule tinnitus therapy
Read More
FDA grants deflazacort orphan drug designation for pediatric juvenile idiopathic arthritis
Read More
Ares Trading patents novel INF-beta protein analogues
Read More
Amakem presents LIMK-1 and/or LIMK-2 inhibitors
Read More
Merck & Co. discloses TrKA inhibitors
Read More
Emory University develops AEP inhibitors
Read More
Arrowhead describes targeted RNAi therapeutics for HBV, renal cell carcinoma, cardiovascular disease
Read More
XOMA starts phase II trial of XOMA-358 in patients with congenital hyperinsulinism
Read More
Aeglea BioTherapeutics doses first patient in phase I study of AEB-1102 for solid tumors
Read More
Mast Therapeutics begins phase II study of vepoloxamer for chronic heart failure
Read More
RedHill Biopharma reports topline results from phase I trial of Yeliva
Read More
CHMP recommends extension of approval of rilpivirine to adolescents with HIV infection
Read More
Phase I trial of ISIS-GSK4-LRx triggers milestone payment to Isis Pharmaceuticals
Read More
Pembrolizumab superior to docetaxel in overall survival of patients with advanced NSCLC
Read More
MMP-12 inhibitors described in recent Bayer Schering Pharma patents
Read More
Bristol-Myers Squibb reports HIV maturation inhibitors
Read More
